Gambro and Nephrogen - new partner for regenerative medicine program
In February 2005, Gambro announced that it would invest around MSEK 100 over three years in the field of regenerative medicine. The funds will be used for internal research as well as to support outside collaborators such as Nephrogen. The next three years funds will finance cell selection and expansion technology and clinical trials. Gambro will primarily focus on developing new tools for cell handling and processing, while Nephrogen will contribute with scientific and clinical expertise. The objective with the current program is to publish first clinical results in two to three years.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.